Skip navigation
FACT
Focus on Alternative and Complementary Therapies

Adverse drug reactions – a systematic review of scales, algorithms and guidelines for causality assessment

Jimoh T1, Ernst E1, Savović J2
1Complementary Medicine, Peninsula Medical School, Universities of Exeter and Plymouth, 25 Victoria Park Road, Exeter EX2 4NT, UK
2Department of Social Medicine, University of Bristol, 1.14 Canynge Hall, Whiteladies Road, Bristol BS8 2PR, UK

Objective

The aim of this review was to summarise existing causality assessment methods for adverse drug reactions (ADR) and to discuss their strengths and weaknesses.

Materials and methods

We conducted electronic searches in Medline (via Pubmed), Embase and the Cochrane databases to find all assessment methods.

Results

Thirty-two different methods were found, falling into three broad categories: expert judgments, algorithms and probabilistic or Bayesian approaches. Expert judgments are individual assessments based on previous knowledge and experience in the field using no standardised tool to arrive at conclusions. Algorithms consist of a set of specific questions with scores for calculating the likelihood of a cause/effect relationship. Bayesian approaches use specific findings in a case to transform the prior estimate of probability into a posterior estimate of probability of drug causation. The prior probability is calculated from epidemiologic information and the posterior probability combines this background information with the evidence in the individual case to generate an estimate of causation. Different causality categories are adopted in each method and the categories are assessed using different criteria. Because assessment methods are also not entirely devoid of individual judgment, inter-rater reliability can be low.

Conclusion

Due to problems of reproducibility and validity, no single method is currently universally accepted. There is an urgent need for an ADR assessment method which is simple, valid and reproducible.

Acknowledgements

TJ is supported by a research fellowship provided by Dr Wilmar Schwabe Pharmaceuticals.

Top | Next: What does effectiveness mean for people with fibromyalgia?»
© Pharmaceutical Press 2008
Accessibility | Terms and Conditions